Progenics Pharmaceuticals to Present at JMP Securities Healthcare Conference
TARRYTOWN, N.Y., July 2, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will make a
presentation on Wednesday, July 10^th at 9:00 AM EDT at the JMP Securities
Healthcare Conference in New York City. The company overview will be webcast
live via a link on the Events page of Progenics' website and archived there
for 30 days.
Progenics Pharmaceuticals, Inc. develops innovative medicines for oncology,
and has a pipeline that includes product candidates in preclinical through
late-stage development. Progenics' first commercial product, Relistor^®
(methylnaltrexone bromide) for opioid-induced constipation, is marketed and in
further development by Salix Pharmaceuticals, Ltd. for markets worldwide other
than Japan, where Ono Pharmaceutical Co., Ltd. is developing the subcutaneous
formulation. For additional information, please visit www.progenics.com.
Additional information concerning Progenics and its business may be available
in press releases or other announcements and public filings made after this
CONTACT: Kathleen Fredriksen
Press spacebar to pause and continue. Press esc to stop.